Competitors such as Beam Therapeutics and Tessera Therapeutics are making progress with their own gene editing technologies, which could potentially offer advantages over CRISPR's approach.

Macquarie University researchers have worked with an international team of scientists to achieve a major milestone in synthetic biology by completing the creation of the final chromosome in the ...

One company currently utilising this approach is Tessera Therapeutics, which emerged in 2020 and was able to secure $300 million earlier this year, in a recent Series C financing round.

Sigilon Therapeutics, Syros Pharma, Tessera, Valo, and Vesalius. Paul Biondi, president of Flagship's Pioneering Medicines unit, said the partnership gets underway with "a shared vision of ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...

Shares of Summit Therapeutics (NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...